Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Jan 4, 2024

31100_dirs_2024-01-04_4b4485d8-b6d0-407f-a208-ed53a2b55756.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-01-02

Reporting Person: Lukatch Heath (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-01-02 Common Stock M 13000 $16.00 Acquired 18625 Direct
2024-01-02 Common Stock S 1101 $62.853 Disposed 17524 Direct
2024-01-02 Common Stock S 7444 $63.552 Disposed 10080 Direct
2024-01-02 Common Stock S 4164 $64.28 Disposed 5916 Direct
2024-01-02 Common Stock S 291 $65.192 Disposed 5625 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-01-02 Stock Option (right to buy) $16.00 M 13000 Disposed 2030-06-10 Common Stock (13000) Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.01 to $64.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $64.015 to $64.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $65.12 to $65.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: Fully vested and exercisable.